(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -12.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
C4 Therapeutics's revenue in 2025 is $30,108,000.On average, 8 Wall Street analysts forecast CCCC's revenue for 2025 to be $3,181,991,086, with the lowest CCCC revenue forecast at $2,659,331,630, and the highest CCCC revenue forecast at $3,663,365,000. On average, 8 Wall Street analysts forecast CCCC's revenue for 2026 to be $2,135,218,457, with the lowest CCCC revenue forecast at $0, and the highest CCCC revenue forecast at $4,070,405,556.
In 2027, CCCC is forecast to generate $2,135,218,457 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,561,604,862.